Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04110288 · ClinicalTrials.gov registry record
VQI DELTA Paclitaxel Device Safety Analysis
A clinical trial, sponsored by Lahey Clinic.
- Completed
- Registry status
- 219,483
- Enrollment target
NCT04110288: Completed study, sponsored by Lahey Clinic.
NCT04110288 is a clinical trial that has completed, run by Lahey Clinic. The registered enrollment target is 219,483 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04110288 has completed, sponsored by Lahey Clinic.
- COMPLETED
- Registry status
- 219,483 participants
- Enrollment target
Study Summary
The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of paclitaxel coated balloons and stents in the treatment of peripheral artery disease (PAD) through analysis of the VQI Peripheral Vascular Intervention (PVI) registry module using the DELTA system.
Primary Outcome
Freedom from death of any cause
Interventions
- DRUG Paclitaxel
- DEVICE Non-drug coated Device Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219,483 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2020-04-01 |
What the finished NCT04110288 record still lists
NCT04110288 is an observational study that tracks outcomes without assigning an intervention. Its 219,483 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Paclitaxel is the first listed.
NCT04110288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04110288 about?
NCT04110288 is a clinical study titled "VQI DELTA Paclitaxel Device Safety Analysis". The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of paclitaxel coated balloons and stents in the treatment of peripheral artery disease (PAD) through analysis of the VQI Peripheral Vascular Intervention (PVI) registry module using the DELTA system.
What is the current status of trial NCT04110288?
This trial is currently completed. The enrollment target is 219,483 participants. The study started on 2017-01-01. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT04110288?
The interventions under investigation include: Paclitaxel (DRUG), Non-drug coated Device Treatment (DEVICE).
Who is sponsoring clinical trial NCT04110288?
This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI